vs
Aardvark Therapeutics, Inc.（AARD）与雅培（ABT）财务数据对比。点击上方公司名可切换其他公司
Aardvark Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对炎症、代谢类疾病及罕见病的新型靶向疗法，核心管线聚焦G蛋白偶联受体相关药物，主要服务北美及全球患者群体，开展医药研发领域合作。
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
AARD vs ABT — 直观对比
营收规模更大
ABT
是对方的Infinity倍
$0
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $11.5B |
| 净利润 | $-17.6M | $1.8B |
| 毛利率 | — | 57.0% |
| 营业利润率 | — | 19.6% |
| 净利率 | — | 15.5% |
| 营收同比 | — | 4.4% |
| 净利润同比 | — | -80.8% |
| 每股收益（稀释后） | $-0.81 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AARDABT
| Q4 25 | $0 | $11.5B | ||
| Q3 25 | $0 | $11.4B | ||
| Q2 25 | $0 | $11.1B | ||
| Q1 25 | $0 | $10.4B | ||
| Q4 24 | — | $11.0B | ||
| Q3 24 | — | $10.6B | ||
| Q2 24 | — | $10.4B | ||
| Q1 24 | — | $10.0B |
净利润AARDABT
| Q4 25 | $-17.6M | $1.8B | ||
| Q3 25 | $-16.3M | $1.6B | ||
| Q2 25 | $-14.4M | $1.8B | ||
| Q1 25 | $-9.3M | $1.3B | ||
| Q4 24 | — | $9.2B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.2B |
毛利率AARDABT
| Q4 25 | — | 57.0% | ||
| Q3 25 | — | 55.4% | ||
| Q2 25 | — | 56.4% | ||
| Q1 25 | — | 56.9% | ||
| Q4 24 | — | 55.0% | ||
| Q3 24 | — | 55.8% | ||
| Q2 24 | — | 55.6% | ||
| Q1 24 | — | 55.2% |
营业利润率AARDABT
| Q4 25 | — | 19.6% | ||
| Q3 25 | — | 18.1% | ||
| Q2 25 | — | 18.4% | ||
| Q1 25 | — | 16.3% | ||
| Q4 24 | — | 17.4% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 16.1% | ||
| Q1 24 | — | 13.9% |
净利率AARDABT
| Q4 25 | — | 15.5% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | — | 84.1% | ||
| Q3 24 | — | 15.5% | ||
| Q2 24 | — | 12.5% | ||
| Q1 24 | — | 12.3% |
每股收益（稀释后）AARDABT
| Q4 25 | $-0.81 | $1.01 | ||
| Q3 25 | $-0.75 | $0.94 | ||
| Q2 25 | $-0.66 | $1.01 | ||
| Q1 25 | $-0.71 | $0.76 | ||
| Q4 24 | — | $5.26 | ||
| Q3 24 | — | $0.94 | ||
| Q2 24 | — | $0.74 | ||
| Q1 24 | — | $0.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $110.0M | $8.9B |
| 总债务越低越好 | — | $12.9B |
| 股东权益账面价值 | $106.6M | $52.1B |
| 总资产 | $117.2M | $86.7B |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资AARDABT
| Q4 25 | $110.0M | $8.9B | ||
| Q3 25 | $126.3M | $7.7B | ||
| Q2 25 | $141.8M | $7.3B | ||
| Q1 25 | $151.3M | $6.8B | ||
| Q4 24 | — | $8.0B | ||
| Q3 24 | — | $7.8B | ||
| Q2 24 | — | $7.2B | ||
| Q1 24 | — | $6.7B |
总债务AARDABT
| Q4 25 | — | $12.9B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $14.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AARDABT
| Q4 25 | $106.6M | $52.1B | ||
| Q3 25 | $122.4M | $51.0B | ||
| Q2 25 | $136.9M | $50.6B | ||
| Q1 25 | $150.7M | $48.8B | ||
| Q4 24 | — | $47.7B | ||
| Q3 24 | — | $39.8B | ||
| Q2 24 | — | $39.3B | ||
| Q1 24 | — | $38.8B |
总资产AARDABT
| Q4 25 | $117.2M | $86.7B | ||
| Q3 25 | $133.2M | $84.2B | ||
| Q2 25 | $147.5M | $84.0B | ||
| Q1 25 | $157.0M | $81.4B | ||
| Q4 24 | — | $81.4B | ||
| Q3 24 | — | $74.4B | ||
| Q2 24 | — | $73.0B | ||
| Q1 24 | — | $72.5B |
负债/权益比AARDABT
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.8M | $3.3B |
| 自由现金流经营现金流 - 资本支出 | — | $2.6B |
| 自由现金流率自由现金流/营收 | — | 22.9% |
| 资本支出强度资本支出/营收 | — | 6.0% |
| 现金转化率经营现金流/净利润 | — | 1.87× |
| 过去12个月自由现金流最近4个季度 | — | $7.4B |
8季度趋势，按日历期对齐
经营现金流AARDABT
| Q4 25 | $-16.8M | $3.3B | ||
| Q3 25 | $-16.1M | $2.8B | ||
| Q2 25 | $-9.8M | $2.0B | ||
| Q1 25 | $-11.4M | $1.4B | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.0B |
自由现金流AARDABT
| Q4 25 | — | $2.6B | ||
| Q3 25 | $-16.1M | $2.3B | ||
| Q2 25 | $-9.9M | $1.5B | ||
| Q1 25 | — | $933.0M | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $627.0M |
自由现金流率AARDABT
| Q4 25 | — | 22.9% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 13.9% | ||
| Q1 25 | — | 9.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 20.2% | ||
| Q2 24 | — | 13.8% | ||
| Q1 24 | — | 6.3% |
资本支出强度AARDABT
| Q4 25 | — | 6.0% | ||
| Q3 25 | — | 4.4% | ||
| Q2 25 | — | 4.5% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 6.6% | ||
| Q3 24 | — | 5.2% | ||
| Q2 24 | — | 5.1% | ||
| Q1 24 | — | 4.0% |
现金转化率AARDABT
| Q4 25 | — | 1.87× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.15× | ||
| Q1 25 | — | 1.07× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 1.64× | ||
| Q2 24 | — | 1.51× | ||
| Q1 24 | — | 0.84× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
